159 related articles for article (PubMed ID: 35068084)
1. A Dual-Filtration System for Single-Cell Sequencing of Circulating Tumor Cells and Clusters in HCC.
Chen VL; Huang Q; Harouaka R; Du Y; Lok AS; Parikh ND; Garmire LX; Wicha MS
Hepatol Commun; 2022 Jun; 6(6):1482-1491. PubMed ID: 35068084
[TBL] [Abstract][Full Text] [Related]
2. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.
Court CM; Hou S; Winograd P; Segel NH; Li QW; Zhu Y; Sadeghi S; Finn RS; Ganapathy E; Song M; French SW; Naini BV; Sho S; Kaldas FM; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
Liver Transpl; 2018 Jul; 24(7):946-960. PubMed ID: 29624843
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease.
Li YM; Xu SC; Li J; Han KQ; Pi HF; Zheng L; Zuo GH; Huang XB; Li HY; Zhao HZ; Yu ZP; Zhou Z; Liang P
Cell Death Dis; 2013 Oct; 4(10):e831. PubMed ID: 24091674
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma.
Qi LN; Xiang BD; Wu FX; Ye JZ; Zhong JH; Wang YY; Chen YY; Chen ZS; Ma L; Chen J; Gong WF; Han ZG; Lu Y; Shang JJ; Li LQ
Cancer Res; 2018 Aug; 78(16):4731-4744. PubMed ID: 29915159
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
[TBL] [Abstract][Full Text] [Related]
6. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
7. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
Zhou Y; Wang B; Wu J; Zhang C; Zhou Y; Yang X; Zhou J; Guo W; Fan J
BMC Cancer; 2016 Jul; 16():506. PubMed ID: 27439521
[TBL] [Abstract][Full Text] [Related]
8. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling.
Pu XY; Zheng DF; Shen A; Gu HT; Wei XF; Mou T; Zhang JB; Liu R
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):408-415. PubMed ID: 30201411
[TBL] [Abstract][Full Text] [Related]
9. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
10. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.
Karaosmanoğlu O; Banerjee S; Sivas H
Cell Oncol (Dordr); 2018 Aug; 41(4):439-453. PubMed ID: 29858962
[TBL] [Abstract][Full Text] [Related]
11. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
12. A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer.
Nam SJ; Yeo HY; Chang HJ; Kim BH; Hong EK; Park JW
Cancer Res Treat; 2016 Oct; 48(4):1229-1242. PubMed ID: 27034142
[TBL] [Abstract][Full Text] [Related]
13. CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging.
Li Y; Chen G; Yan Y; Fan Q
Eur J Pharmacol; 2019 Oct; 860():172589. PubMed ID: 31401158
[TBL] [Abstract][Full Text] [Related]
14. POU2F1 over-expression correlates with poor prognoses and promotes cell growth and epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Zhong Y; Huang H; Chen M; Huang J; Wu Q; Yan GR; Chen D
Oncotarget; 2017 Jul; 8(27):44082-44095. PubMed ID: 28489585
[TBL] [Abstract][Full Text] [Related]
15. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
17. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
Song FN; Duan M; Liu LZ; Wang ZC; Shi JY; Yang LX; Zhou J; Fan J; Gao Q; Wang XY
PLoS One; 2014; 9(9):e108507. PubMed ID: 25268581
[TBL] [Abstract][Full Text] [Related]
18. Follistatin Like 5 (FSTL5) inhibits epithelial to mesenchymal transition in hepatocellular carcinoma.
Zhang DY; Lei JS; Sun WL; Wang DD; Lu Z
Chin Med J (Engl); 2020 Aug; 133(15):1798-1804. PubMed ID: 32740091
[TBL] [Abstract][Full Text] [Related]
19. High expression of WSB1 is associated with poor prognosis in hepatocellular carcinoma and affects epithelial-mesenchymal transition.
Xu H; Han H; Tian G
J BUON; 2020; 25(4):1890-1896. PubMed ID: 33099929
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
